Differentiated thyroid cancers (DTCs), such as papillary (PTC) and follicular (FTC) thyroid cancer, respond well to standard radioactive iodine (RAI) therapy, which relies on the sodium/iodide symporter (NIS) for iodine uptake [5,6]. This evidence concerns the gene SLC5A5 and thyroid cancer.